

A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

NCT06468228

Status	RECRUITING
Phase	Phase 3
Sponsor	AbbVie
Enrollment	1,280 participants

Key Eligibility Criteria

Inclusion (4)

- Diagnosis of moderate to severe HS for at least 6 months prior to Baseline as determined by the investigator (i.e., through medical history and interview of participant).
- Total abscess and inflammatory nodule (AN) count of e 5 at Baseline
- Hidradenitis suppurativa (HS) lesions present in at least two distinct anatomic areas at Baseline.
- At least 1 anatomic area of HS involvement characterized as Hurley Stage II or higher at Baseline.

Exclusion (3)

- Any evidence of Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Confirmed positive anti-HIV antibody (HIV Ab) test.
- Evidence of active tuberculosis or meets tuberculosis exclusionary parameter

Locations (279 total)

Cahaba Dermatology & Skin Health Center /ID# 263795, Birmingham, Alabama, United States
Medical Dermatology Specialists /ID# 263394, Phoenix, Arizona, United States
Banner University Medicine Dermatology /ID# 263557, Tucson, Arizona, United States
... and 276 more locations